Table 5.

Logarithm of the minimum angle of resolution (logMAR) visual acuity of the study subjects with or without central corneal epitheliopathy (CCE) in the intense pulsed light (IPL)—meibomian gland expression (MGX) group (n = 12 and 32, respectively) and MGX (control) group (n = 11 and 29, respectively) at baseline as well as 1 and 3 months after the final treatment session.

	Group	Baseline		1 Month after the Final Treatment Session				3 Months after the Final Treatment Session
		Mean ± SD	Adjusted p Value for IPL-MGX vs. Control	Mean ± SD	Mean Change ± SE	Adjusted p Value vs. Baseline	Adjusted p Value for IPL-MGX vs. Control	Mean ± SD	Mean Change ± SE	Adjusted p Value vs. Baseline	Adjusted p Value for IPL-MGX vs. Control
Total	Control	0.23 ± 0.22	1	0.23 ± 0.22	0.00 ± 0.00	1	1	0.23 ± 0.22	0.01 ± 0.01	0.8	1
	IPL-MGX	0.22 ± 0.21		0.20 ± 0.21	−0.02 ± 0.01	<0.001 **		0.20 ± 0.21	−0.02 ± 0.01	0.003 *
Without CCE	Control	0.20 ± 0.24	1	0.19 ± 0.24	−0.01 ± 0.00	0.62	1	0.20 ± 0.23	0.00 ± 0.01	1	1
	IPL-MGX	0.23 ± 0.22		0.22 ± 0.23	−0.01 ± 0.00	0.089		0.22 ± 0.22	−0.01 ± 0.01	0.34
With CCE	Control	0.31 ± 0.14	0.26	0.31 ± 0.13	0.01 ± 0.01	1	0.036 *	0.32 ± 0.15	0.01 ± 0.02	1	0.030 *
	IPL-MGX	0.19 ± 0.17		0.14 ± 0.16	−0.05 ± 0.01	0.016 *		0.14 ± 0.14	−0.05 ± 0.01	0.016 *

p values were determined with the Wilcoxon signed-rank test vs. baseline or Mann–Whitney U test vs. control with Bonferroni’s correction (* adjusted p < 0.05, ** adjusted p < 0.001). SE; standard errors, SD; standard deviations.